As Nvidia stock takes aim at another record high and market-cap dominance, AMD and TSM set up alongside two top drugmakers.
By Thomas A. Sternberg, CFA, Partner and Dasha Fomina
The market for GLP-1 drugs could soar to $130 billion by 2030